Actavis Introduces Generic Requip XL

Actavis has received FDA approval for Ropinirole Extended-Release Tablets, 2mg, 4mg, 6mg, 8mg, and 12mg, a generic equivalent to Requip XL (GlaxoSmithKline). Distribution of the product has commenced.

Requip XL is an orally administered, non-ergoline dopamine agonist indicated for the treatment of the signs and symptoms idiopathic Parkinson's disease. The precise mechanism of action of ropinirole as a treatment for Parkinson's disease is unknown, although it is believed to be due to stimulation of postsynaptic dopamine D2-type receptors within the caudate-putamen in the brain.

For more information call (973) 993-4500 or visit www.actavis.us.